Annual Meeting Webinar #8: Developmental Therapeutics in Gynecologic Cancer

All times listed are Central Daylight Time (CDT).

Moderators/Distillants: Kunle O. Odunsi, MD, PhD, and Debra L. Richardson, MD

• A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC): Genomic sequencing and updated efficacy results – R. E. O’Cearbhaill
• Pembrolizumab window study: Illuminating the immunologic landscape in gynecologic cancers – S. Gaillard
• Intraperitoneal or subcutaneously administered IL-15 superagonist (N-803) increases NK cell cytotoxicity in ovarian cancer – M. Geller
• A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC) – R. E. O’Cearbhaill
• A phase 1 study of XMT-1536 in patients with solid tumors likely to express NaPi2b: A summary of dose escalation – D. Richardson

Moderators to synthesize these 4 abstracts with input from the authors:

• Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer (EOC): The SIERRA multi-institutional open-label phase Ib trial
• A phase Ib study of navicixizumab and weekly paclitaxel in heavily pretreated platinum resistant ovarian, primary peritoneal or fallopian tube cancer
• A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma
• Apatinib plus camrelizumab in patients with advanced cervical cancer: A multicentre, open-label, single-arm, phase II trial

Download Abstract (PDF)

ACCESS FULL SERIES (NON-CE) | REGISTRATION FOR CE

Learning Objectives

1. Identify tumor genomic markers that may predict response to PLD based therapies
2. Describe tumoral changes in PD-L1 modified proportion score and immune environment after exposure to pembrolizumab
3. Demonstrate the effect an IL-15 superagonist (N-803) has on the immune microenvironment in the peritoneal cavity and peripheral blood when administered weekly as maintenance therapy in a Phase II clinical trial.
4. Describe the safety and efficacy of CAR T cells targeting muc16ecto in ovarian cancer
5. Review the safety and efficacy of XMT-1536, an ADC targeting NaPi2b

Joint Accreditation

In support of improving patient care, the Society of Gynecologic Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

AMA Credit Designation Statement – Physicians

The Society of Gynecology Oncology designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation on each activity.

ANCC Credit Designation Statement – Nurses

This activity has been approved for a maximum of 1.0 nursing contact hours.

ACPE Credit Designation Statement – Pharmacists

Each activity has been approved for a maximum of 1.0 contact hours of pharmacy continuing education credit. UAN number JA00007238-0000-20-012-L01-P.

PAs may claim a maximum of 1.0 AMA PRA Category 1 Credits™ for completing this live activity. NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state or medical society.